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While previous studies suggest the implication of herpes simplex virus (HSV) in the onset of Alzheimer’s disease (AD), no study has
investigated its association with early neuroimaging markers of AD. In the Three-City and the AMI cohorts, the associations between
HSV infection and (i) hippocampal volume (n= 349), (ii) white matter alterations in the parahippocampal cingulum and fornix using
diffusion tensor imaging (n= 260), and (iii) incidence of AD (n= 1599) were assessed according to APOE4 status. Regardless of
APOE4 status, infected subjects presented (i) significantly more microstructural alterations of the parahippocampal cingulum and
fornix, (ii) lower hippocampal volumes only when their anti-HSV IgG level was in the highest tercile—reflecting possibly more
frequent reactivations of the virus (p= 0.03 for subjects with a high anti-HSV IgG level while there was no association for all infected
subjects, p= 0.19), and (iii) had no increased risk of developing AD. Nevertheless, among APOE4 carriers, infected subjects
presented lower hippocampal volumes, although not significant (p= 0.09), and a two or three times higher risk of developing AD
(adjusted Hazard ratio (aHR)= 2.72 [1.07–6.91] p= 0.04 for infected subjects and aHR= 3.87 [1.45–10.28] p= 0.007 for infected
subjects with an anti-HSV IgG level in the highest tercile) while no association was found among APOE4 noncarriers. Our findings
support an association between HSV infection and AD and a potential interaction between HSV status and APOE4. This reinforces
the need to further investigate the infectious hypothesis of AD, especially the associated susceptibility factors and the possibility of
preventive treatments.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disease char-
acterized by visible changes within the brain several years before
the clinical stage of dementia [1], including hippocampal atrophy
and microstructural alterations of white matter (WM) [2–5].
Nevertheless, although the temporality and topography of the
clinical and biological markers of AD have been better described,
the cause of the disease remains misunderstood.
Several studies have suggested the implication of infectious
agents in AD pathophysiology [6], with herpes simplex virus type 1
(HSV-1) being one of the most investigated candidates [7, 8]. In
fact, the implication of HSV-1 could potentially explain the
location, chronology and the type of damage described in AD.
First, HSV-1 is a neurotropic virus with a particular tropism for the
temporal cortex, as shown by the localization of lesions in HSV-1
encephalitis and postmortem studies highlighting the presence of
HSV DNA in the brains of older adults (reviewed in [9]). HSV-1 also
has the ability to move from neurons to neurons, which could
explain the progression of lesions to other brain areas [10, 11].
Second, HSV-1, which remains in a latent state throughout life
after primary infection, can periodically reactivate during a
temporary immune decline. With advancing age, the development
of a long-lasting immunosenescence [12, 13] may allow more
frequent and/or more intense reactivations of the virus [14],
thereby explaining the progressive and relatively late onset of AD.
Third, insights from in vitro and animal studies revealed that the
inoculation of HSV-1 leads to the development of the main
hallmarks of AD, in particular neuro-inflammation, amyloid
deposits, and phosphorylated Tau (reviewed in [15, 16]), and that
the accumulation of the peptide Aβ may be due to its potential
antimicrobial role [6, 17, 18]. Finally, HSV-1 could be linked to
genetic risk factors of AD [19, 20], especially APOE4. The existence
of such genetic susceptibility factors could explain why, despite a
seroprevalence of ~80% in the elderly [21], some infected
individuals remain “healthy carriers”, while others develop clinical
consequences of the infection.
However, results from epidemiological studies are still incon-
sistent concerning the association between HSV infection and
cognitive decline or dementia (reviewed in [22]) and, if HSV has
been related to gray matter volume among AD patients [23–25],
no study has investigated its association with earlier neuroimaging
markers of AD among the elderly.
In the present study, we aimed to evaluate the association
between HSV status and (i) hippocampal volume (HV), (ii) WM
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alterations in the cingulum and the fornix which are the main
afferent and efferent axonal bundles of the hippocampus in two
population-based prospective cohorts of older adults. We also
complement our previous results [26] in a larger study sample
regarding its association with dementia incidence.
MATERIALS AND METHODS
Design and participants
The study sample comes from two population-based prospective cohorts:
the Three-City study (3C) and the Aging Multidisciplinary Investigation
study (AMI). A detailed description of both study protocols was previously
published [27, 28]. Briefly, the 3C cohort initially aims to assess the effect of
vascular factors on cognitive impairment in three French areas (Bordeaux,
Dijon, and Montpellier). In Bordeaux, 2104 participants aged 65 years or
older, non-institutionalized, and enrolled from electoral lists were included
in 1999–2001. The AMI cohort aims to study health and aging among the
elderly population living in rural settings. In 2007–2009, 1002 retired
farmworkers or owners from the south-west of France who were aged
65 years or older were enrolled from the reimbursement database of the
French Farmer Health Insurance System. Data on sociodemographic status,
lifestyle, and health were collected during home visits 2, 4, 7, 10, 12, and
14 years and 2, 4, and 7 years after inclusion, respectively, for 3C and AMI.
The Ethical Committee of the University Hospital of Kremlin-Bicêtre and
Sud-Mediterranée III for 3C and of Bordeaux for AMI approved the research
protocol. Each participant provided signed informed consent.
Determination of HSV status
HSV serologies were based on blood samples provided at the 4-year follow-
up visit for 3C (n= 1258) and at inclusion for AMI (n= 609) (Supplementary
Fig. 1). Two types of anti-HSV antibodies were determined: anti-HSV IgG,
reflecting an infection by the virus, and anti-HSV IgM, possibly representing
a reactivation of the virus in the weeks before blood sampling. We used
LIAISON® HSV-1/2 IgG/IgM tests (Diasorin, Saluggia, Italy—chemilumines-
cence immunoassay technology) (details in Supplementary Information).
Participants were excluded if their serology was inconclusive (n= 40) or if
they presented IgG- IgM+ status (n= 5) reflecting either a primary infection
(unlikely given the advanced age of the participants) or IgG false negative
or IgM false positive (Supplementary Fig. 1).
Incidence of AD
In both cohorts, an active screening of cognitive and functional decline was
performed at each visit by a trained neuropsychologist. When cognitive
impairment was suspected, a second evaluation was performed by a
geriatrician or a neurologist to confirm the diagnosis of dementia using the
Diagnostic and Statistical Manual of Mental Disorders Fourth Edition criteria
[29] and to determine the etiology. Each case of dementia was then
reviewed by a committee of experts according to the NINCDS-ADRDA
criteria for AD. For statistical analyses of the incidence of AD (including pure
AD and mixed dementia), we excluded subjects with prevalent dementia at
the time of serology (n= 133) and subjects without any follow-up after the
time of serology (n= 171). Analyses were carried out on 1599 participants
(Supplementary Fig. 1). Among them, the participants from 3C were already
included in previous published results [26].
Magnetic resonance imaging acquisition and processing
Magnetic resonance imaging (MRI) was performed using an ACHIEVA 3T
scanner (Philips Medical System, Netherlands) (details in Supplementary
Information) on a subsample of 238 participants 6 years after the serology
in 3C and 200 participants 4 years after the serology in AMI. Among these
subjects, 387 had anti-HSV serologies.
3D T1 weighted images were used to segment the hippocampus using
FIRST implemented in FMRIB Software Library v5.0 (FSL, [30]). The quality of
segmentation was checked manually for each subject with minimal manual
editing if necessary. A total of 35 participants had no available measure of
the HV and three participants were already demented at the time of the
serology, resulting in the inclusion of 349 subjects in this analysis
(Supplementary Fig. 1). Right and left HVs were extracted, averaged, and
expressed as a percentage of the total intracranial volume (TIV).
WM integrity was assessed using diffusion tensor imaging (DTI). Of 387
participants initially included in the MRI study, 259 participants had
available diffusion-weighted images (Supplementary Fig. 1). None of them
were demented at the time of the serology. Briefly, diffusion-weighted
images (DWI) were co-registered to the reference b0 volume with an affine
transformation and were corrected for motion and eddy current
distortions. The four successive DWI runs were then averaged and
fractional anisotropy (FA), mean diffusivity (MD), and axial and radial
diffusivities (AxD, RD) maps were obtained by fitting a tensor model using
FMRIB’s Diffusion Toolbox (FDT), part of FSL. FA, MD, AxD, and RD maps
were nonlinearly registered to the FMRIB58-FA template and then affine
transformed to the MNI152 space using the Tract Based Spatial Statistics
pipeline [31]. Mean FA and diffusivity values were extracted on the
registered diffusion maps within a study-specific mean WM skeleton mask
(threshold: 0.2) using fslmeants function for two axonal bundles: the fornix
and the cingulum in the portion running along the hippocampus, as
defined in the Johns Hopkins University atlas (stria terminalis of the fornix
and hippocampal cingulum). We focused on the fornix and the cingulum
as they are the main afferent and efferent axonal bundles of the
hippocampus. In consequence, they are considered as particularly
interesting biomarkers in the amnesic form of Alzheimer’s disease and
several studies have highlighted alterations of white matter microstructure
in these bundles from the early stages of the disease [2–5]. FA ranges from
0 to 1 and evaluates the directionality of water diffusion in the brain. In
WM, an FA value close to 1 indicates that water molecules preferentially
move in one main direction (anisotropic motion), along axonal fibers. MD
represents the average amplitude of water diffusion movements measured
in the three space directions (x,y,z), AxD the diffusivity in the main direction
and RD the average of the diffusivity in the two remaining directions. High
FA and low diffusivity values reflect a high level of structural coherence
and undamaged axon fiber architecture.
Statistical analysis
For analyses of HV and WM integrity, we considered only IgG antibodies
because small sample sizes prevented us from analyzing IgM. Both the
presence and the levels of IgG in terciles were considered. The use of a
continuous variable for IgG levels was not possible due to the presence of
an upper limit of quantification. Linear regression models adjusted for age
at serology, sex, level of education, presence of at least one allele of
APOE4, hypertension, diabetes, and cohort were performed. Normality
of residuals and homoscedasticity were assessed using a histogram of
residuals, a normal quantile-quantile plot of residuals, and a plot of
residuals versus predicted values.
For analyses of the incidence of AD, we considered the presence of IgG
and IgG levels in terciles. The existence of an interaction with time
prevented us from analyzing the IgM status. Cox models, using age as
timescale, were performed [32]. The results are presented as the cause-
specific hazard ratios (HRs) with their 95% confidence intervals (95% CIs)
and p-values. Age at dementia onset (AD or other types) was defined as
the middle of the time interval between the last visit without dementia
and the diagnosis visit. Participants who developed another type of
dementia were censored at the age of onset of dementia. Nondemented
participants (included the deceased without dementia) were censored at
the age of the last visit without dementia. We considered the following
confounding factors in addition to age (as timescale): sex, level of
education, marital status, presence of at least one allele of APOE4,
hypertension, diabetes, hypercholesterolemia, tobacco use, and cohort.
The proportional hazards assumption was assessed with Schoenfeld
residuals and by testing interactions with time.
For all analyses, we tested the existence of an interaction between
APOE4 and HSV status. As we assumed a priori a different impact of HSV
infection according to the APOE4 status, analyses were then systematically
stratified by APOE4. In the stratified models, due to the small sample sizes,
the adjustment variables were restricted to age, sex, and cohort for linear
regression models and to age (as a timescale), sex, level of education, and
cohort for Cox models. For the same reason, we did not consider the levels
of IgG in terciles in the stratified samples.
All statistical tests were two-tailed, and the threshold for statistical




The characteristics of participants are presented in Table 1 in the
three studied samples: HV (n= 349), WM integrity (n= 259), and
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AD incidence (n= 1599). In the latter, participants were 77 (±5)
years old, 45% were male and 18% were APOE4 carriers. In this
sample 83% (n= 1327) had anti-HSV IgG and these tended to be
more often women, widowed, with a lower level of education,
more hypertension, and more often non-smoker (Supplementary
Table 1).
Association between HSV status and HV
Among the available sample, 80.5% (n= 281) had anti-HSV IgG.
The mean HV expressed as a percentage of the TIV was 0.25 ± 0.03
(Table 2).
In non-stratified analyses (Table 3), there was no significant
difference in HV between infected and uninfected subjects (p=
0.19). Nevertheless, when considering the levels of IgG in terciles,
subjects with an IgG level in the highest tercile had a lower HV
compared to uninfected subjects (β=−0.011 standard deviation
= 0.005, p= 0.03) (Fig. 1).
The p-value of the interaction between the presence of anti-HSV
IgG and APOE4 was equal to 0.15 (Table 3). In APOE4 carriers
(n= 69), the association between the presence of IgG and lower
HVs was close to significance (β=−0.016 standard deviation=
0.009 p= 0.09). No association was observed among APOE4
noncarriers (n= 262, p= 0.71).
Association between HSV status and WM microstructural
integrity
Among the available sample, 80% (n= 206) had anti-HSV IgG. FA,
MD, AxD, and RD for the parahippocampal cingulum and fornix
are presented in Table 2. Regardless of APOE4 status (Table 3), the
presence of anti-HSV IgG was significantly associated with low FA,
high MD, and high RD of the parahippocampal cingulum and
fornix. No significant associations were observed between the
presence of IgG and AxD. Although there were significant
associations for several IgG terciles, there were no clear trend
for an increase in DTI alterations with increasing IgG levels (Fig. 1).
There were no significant interaction between the presence of
anti-HSV IgG and APOE4 for DTI parameters (Table 3, p-values ≥
0.33). There were associations at least borderline significant
Table 1. Characteristics of participants included in analyses on hippocampal volume, white matter integrity, and incidence of AD.
Sample for hippocampal volume
analyses (N= 349) N (%)
Sample for white matter integrity
analyses (N= 259) N (%)
Sample for incidence of AD
analyses (N= 1599) N (%)
Age
Mean (standard deviation) 74.1 (4.5) 73.9 (4.3) 76.7 (5.3)
Minimum/maximum 65.9/85.3 65.9/85.0 65.7/96.1
Sex




70 (20.1) 51 (19.7) 361 (22.6)
Short secondary school 165 (47.3) 118 (45.6) 787 (49.2)
Higher levels 114 (32.7) 90 (34.7) 451 (28.2)
Marital statusa
Married 232 (66.7) 174 (67.2) 934 (58.5)
Widowed 79 (22.7) 57 (22.0) 470 (29.4)
Single or divorced or separate 37 (10.6) 28 (10.8) 192 (12.0)
APOE4a
At least one allele 69 (20.8) 51 (20.9) 271 (17.5)
Hypertensiona,b
Presence 258 (74.1) 186 (72.1) 1266 (79.3)
Diabetesa,b
Presence 26 (7.4) 17 (6.6) 199 (12.5)
Hypercholesterolemiaa,b
Presence 204 (58.5) 155 (59.8) 933 (58.4)
Tobacco consumptiona
Former or current smoker 121 (34.7) 91 (35.1) 555 (34.8)
Anti-HSV IgG
Positive 281 (80.5) 206 (79.5) 1327 (83.0)
Anti-HSV IgM
Positive 11 (3.2) 9 (3.5) 61 (3.8)
3C and AMI cohorts.
AD Alzheimer’s disease.
aThe number of missing data were 1, 0, and 3 for marital status, 18, 15, and 54 for APOE4, 1, 1, and 3 for hypertension, 0, 0, and 8 for diabetes, 0, 0, and 1 for
hypercholesterolemia, and 0, 0, and 6 for tobacco consumption for the samples used for hippocampal volume analyses, white matter integrity analyses and
incidence of Alzheimer’s disease analyses, respectively.
bHypertension was defined as taking antihypertensive treatment or having blood pressure ≥140/90 mmHg (vs blood pressure <140/90 mmHg without
antihypertensive treatment). Diabetes was defined as taking anti-diabetic treatment or having fasting blood sugar ≥7mmol/L or ≥11 in case of non-fasting
blood sugar (vs fasting blood sugar <7mmol/L or <6.1 in case of non-fasting blood sugar and without anti-diabetic treatment). Hypercholesterolemia was
defined as taking lipid-lowering treatment or having cholesterol level ≥6.2 mmol/L (vs cholesterol level <6.2 mmol/L without lipid-lowering treatment).
M. Linard et al.
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(p ranging from 0.006 to 0.09) between anti-HSV IgG and low FA,
high MD, and high RD among APOE4 noncarriers for the
parahippocampal cingulum and among both ApoE4 carriers and
noncarriers for the parahippocampal fornix.
Association between HSV status and the incidence of AD
Among the 1599 participants, 83% (n= 1327) had anti-HSV IgG.
During the follow-up (mean time= 6.8 years, standard deviation
2.6), 293 cases of dementia were diagnosed, including 222 cases
of AD, with an incidence rate of 20.6 cases of AD per 1000 person-
years. The median time between the serology and diagnosis of AD
was 4.3 years (1st quartile= 1.9, 3rd quartile= 6.8).
In non-stratified analyses (Table 4), there was no significant
association between HSV status and the incidence of AD.
However, the p-value of the interaction between the presence
of anti-HSV IgG and APOE4 was equal to 0.05 (Table 4). In APOE4
carriers (n= 271), the presence of IgG was significantly associated
with an increased risk of AD (aHR= 2.72 [1.07–6.91] p= 0.04) and
subjects with an IgG level in the highest tercile had an increased
risk of AD compared to uninfected subjects (aHR= 3.87
[1.45–10.28] p= 0.007) or compared to infected subjects with an
IgG level in the lowest tercile (aHR= 2.30 [1.08–4.91] p= 0.03). In
APOE4 noncarriers, no significant association was observed.
DISCUSSION
Main results
Our findings suggest an increased risk of AD in subjects infected
by HSV. Infected subjects with an anti-HSV IgG level in the highest
tercile (possibly reflecting more frequent reactivations over time)
had lower HV compared to uninfected subjects. Infected subjects
presented also more microstructural alterations of the parahippo-
campal cingulum and fornix regarding FA, MD, and RD. Our results
are also in favor of an interaction between being infected with
HSV and APOE4 status regarding advanced markers of the disease
(HV and then incidence of AD). Among APOE4 carriers, infected
subjects presented lower HVs, although not significant, and had a
two times higher risk of developing AD and a three times higher
risk if their anti-HSV IgG level was in the highest tercile. Among
APOE4 noncarriers, no associations were observed between HSV
status and HV or incidence of AD.
Strengths and limitations
Our study has several strengths. The cohorts benefit from a
population-based recruitment strategy allowing for the inclu-
sion of participants regardless of their cognitive performance,
unlike clinical studies. Nevertheless, some selection bias
persists (volunteer bias, acceptance of neuroimaging examina-
tion, and blood sampling). As expected, the subjects with brain
imaging data were younger, more educated, less often
widowed, presented less co-morbidities such as hypertension
and diabetes compared to the excluded subjects. It should also
be noted that the frequency of APOE4 was slightly increased in
these groups (Supplementary Table 2). The HSV serology used
has excellent sensitivity and specificity (99 and 97% according
to the manufacturer), and the seroprevalence observed in our
population was in accordance with previous studies [21]. This
serology does not, however, distinguish between HSV-1 and
HSV-2 infections, but it seems to be a minor limitation
regarding the relatively low prevalence of HSV-2 (≈20%)
compared to that of HSV-1 (≈80%) in aged subjects and the
tropism of HSV-2 for genital locations that makes it unlikely to
be involved in the development of AD. Thus, the detection of
both HSV-1 and HSV-2 probably underestimated the observed
associations rather than the opposite. Our study has numerous
and valuable neuroimaging data on both HV and WM integrity.
Therefore, a relatively large number of tests were performed
and may have increased the probability of obtaining some
statistically significant results purely by chance. The availability
of genetic data on APOE4 allowed us to perform stratified
analyses, but, due to the small number of APOE4 carriers,
analyses were adjusted only for a limited number of potential
confounders. Note that, as sensitivity analyses, the stratified
models were also carried out with the full set of adjustment
variables. The results were unchanged except for two analyses
concerning the parahippocampal fornix: the association
became non-significant among the APOE4 carriers for RD (p
= 0.06 vs 0.04) and significant among the APOE4 noncarriers for
FA (p= 0.048 vs 0.06).
Concerning the incidence of AD, the prospective design
allowed for the diagnosis of incident cases over 10 years in 3C
and 7 years in AMI with a low rate of loss to follow-up. An active
screening of dementia cases was performed over the follow-up,
and special attention was paid to the quality of the clinical
diagnosis. Although the availability of AD biomarkers obtained
through lumbar puncture or PET imaging would have enhanced
the accuracy of the etiological diagnosis, their cost, accessibility,
and acceptability prevent their use in these population-based
cohorts.
Interpretation in light of the literature
Associations between the presence of anti-HSV IgG, hippocampal
volume, and WM alterations. Regardless of the APOE status,
infected subjects with an IgG level in the highest tercile (reflecting
more frequent reactivations of the virus [14]) presented lower HVs
compared to uninfected subjects. Infected subjects had also more
microstructural alterations in the parahippocampal cingulum and
fornix, including lower FA, and higher MD and RD, than uninfected
subjects. To our knowledge, this is the first study evaluating the
association between the presence of anti-HSV IgG and HV and WM
integrity in older adults. Previous studies exploring the association
between HSV status and neuroimaging markers were conducted
on different populations. Among AD patients, studies [23–25] have
previously highlighted a positive correlation between the level of
anti-HSV IgG and gray matter volumes, including the volumes in
Table 2. Hippocampal volume and white matter integrity of the




Hippocampal and total intracranial volumes (n= 349)
Total intracranial volume in cm3 1329.3 (127.4) 1054.9/1758.7
Mean hippocampal volume in cm3 3.27 (0.45) 2.05/4.35
Hippocampal volume (% TIV) 0.25 (0.03) 0.15/0.32
DTI parameters (n= 259)
Parahippocampal cingulum
Fractional anisotropy 0.45 (0.04) 0.34/0.56
Mean diffusivity (in 10−6 mm2/s) 772.3 (39.8) 687.3/896.2
Axial diffusivity (in 10−6 mm2/s) 1207.6 (60.7) 1039.7/1367.6
Radial diffusivity (in 10−6 mm2/s) 554.6 (42.7) 453.5/684.7
Parahippocampal fornix
Fractional anisotropy 0.52 (0.04) 0.40/0.62
Mean diffusivity (in 10−6 mm2/s) 808.9 (69.1) 701.3/1148.4
Axial diffusivity (in 10−6 mm2/s) 1305.5 (81.7) 1144.1/1625.5
Radial diffusivity (in 10−6 mm2/s) 560.7 (72.2) 430.9/939.6
3C and AMI cohorts.
TIV total intracranial volume, SD standard deviation, DTI diffusion tensor
imaging.
M. Linard et al.
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the orbitofrontal cortex and temporal poles. In schizophrenic
patients, studies [33–35] revealed an association between HSV
infection and cortical atrophy, especially over frontal regions and
the cingulate cortex. Finally, in five individuals with a history of
HSV-1 encephalitis, a neuroimaging evaluation a few years later
(median time 4 years) [36] revealed no significant difference in HV
or thickness in the contralateral hemisphere compared to 51 age-
matched controls, while a reduction in FA and an increase in MD
and RD parameters were reported in bundles connecting the
medial temporal lobe to other brain areas.
Although white matter alterations can be seen in neurological
pathologies other than AD, the fornix and cingulum bundles are
connecting tracts of the limbic system that are thought to be
altered prematurely in AD processes. Indeed, previous reports
have found significant alterations in DTI parameters in the
cingulum or fornix among AD patients, patients with mild
cognitive impairment (MCI), or cognitively normal adults who
developed amnestic MCI, and these alterations were associated
with memory decline [2–5].
Moreover, while the interpretation of DTI parameters remains
debated [37, 38], alterations of RD are assumed to reflect myelin
damage, suggesting a pathophysiological mechanism underlying
the association between HSV infection and AD. Notably, the
occurrence of demyelination in the central nervous system
following HSV infection was also previously reported in murine
studies [39, 40].
Associations between HSV status and the incidence of AD according
to APOE4 status. Our results highlight an association between
the presence or the level of anti-HSV IgG and an increased risk of
AD among APOE4 carriers while no significant association was
found in the whole sample. Previous studies that have not
stratified on APOE status report conflicting results regarding the
association between the presence of anti-HSV IgG and cognitive
decline or incidence of dementia (reported in [22]) while a
significant increased risk of episodic memory decline was found
among APOE4 carriers within the Betula study [41]. Regardless of
the APOE status, other studies have also observed an increased
risk of AD in subjects with frequent reactivations, identified either
by the presence of IgM [42, 43] or by a high level of IgG [25].
To note, the presence of anti-HSV IgG reflects an infection that
occurred decades before serology, excluding a potential reverse
causality bias. Regarding anti-HSV IgG levels (assumed to reflect
the frequency of viral reactivations since the first contact with the
virus and therefore also for decades), the risk of reverse causation
also seems low. Nevertheless, for this marker, such bias cannot be
fully excluded if early consequences of AD facilitate viral
reactivations and consequently increase the anti-HSV IgG level.
With this in mind, we performed a sensitivity analysis to assess
whether the significant association found between a high anti-
HSV IgG level and incidence of AD in APOE4 carriers could be
explained by such problems. In the subsample of APOE4 carriers,
after excluding subjects who developed an AD dementia within
the subsequent 4 years, the associations remain broadly similar
(Supplementary Table 3).
Interaction between APOE4 and the presence of anti-HSV IgG. Even
if the interaction test was not significant at the level of 0.05, the
results of the stratified analyses support the existence of an
interaction between APOE4 status and the presence of anti-HSV IgG
considering both the risk of AD and lower HVs while no interaction
was observed for WM integrity. This apparent discrepancy might
reflect a differential impact of APOE4 on gray and white matters as
suggested in some studies showing that APOE4 carriers did not
differ from noncarriers in DTI parameters of the cingulum and fornix
bundles [44]. This is consistent with our data where infected APOE4
Fig. 1 Association between the levels of anti-HSV IgG in terciles and hippocampal volume or white matter integrity. Adjusted linear
regression models. 3C and AMI cohorts. T1, T2, and T3: 1st, 2nd, and 3rd terciles of anti-HSV IgG, TIV: total intracranial volume, fornix and
cingulum: parahippocampal fornix and cingulum. The bars show the regression coefficients with their 95% confidence interval (reference:
uninfected subjects). Linear regression models are adjusted for age at serology, sex, level of education, presence of at least one allele of
APOE4, hypertension, diabetes, and cohort.
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carriers had lower HVs while they did not differ from noncarriers
regarding DTI parameters (data not shown).
The existence of such an interaction has been reported in the
literature. Concerning the risk of AD, our observation is in accordance
with results from the Betula Swedish cohort [41, 45], whereas such
interaction was not observed in the PAQUID cohort [43]. The
existence of an interaction between APOE4 and HSV status has
previously been discussed in postmortem studies reporting the
presence of HSV DNA in brain regions of older adults according to
APOE4 status [46–49], but the results remain controversial. More
recently, murine studies have also highlighted an increased HSV-1
load in the brain of APOE4 carriers compared to APOE3 carriers [50–
52], and a pathophysiological explanation has been proposed: HSV-1
and the ApoE protein compete for the same binding site to enter
neurons. ApoE4, competing less efficiently with HSV-1, facilitates the
infection of neurons by the virus [53]. Accordingly, APOE4 status is
related to an increased risk of cold sores [48, 49, 54] and to the
severity of other viral infections (reviewed in [55]).
The existence of such susceptibility factors could explain that not
all the HSV-infected individuals develop AD. However, the
APOE4 status may not be the only susceptibility factor and it would
be interesting to identify other factors: (i) genetic factors as, beyond
APOE4, other genetic risk factors of AD are also linked to HSV [19, 20]
or involved in the immune response; (ii) factors linked to the virus
such as the type of viral strain; or (iii) factors linked to the immune
capacities of the host. Such factors could be useful in distinguishing
between subjects who will develop clinical consequences of the
infection and those who will remain “healthy carriers”.
Conclusion
While the underlying mechanism remains uncertain and may
involve direct action of the virus and/or the immune response
against it, our findings suggest an association between HSV-1
infection and markers of AD pathology. These results reinforce the
need to further investigate the infectious hypothesis of AD,
especially the associated susceptibility factors such as APOE4 and
the possibility of preventive treatments.
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